RNAseq data on an independent patient cohort showed reduced G0S2 expression in patients with myeloid BP‐CML and kinase‐independent TKI resistance (Figure 1C,D). Here, G0S2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.